- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01985789
Anti-histamines and Methacholine Challenges.
April 7, 2015 updated by: Don Cockcroft
The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients
The asthmatic airway is identified and studied using inhaled agents such as histamine and methacholine.
The use of antihistamines prior to the test will inhibit the test result if histamine is used to cause airway constriction.
If using methacholine, this may also be true depending on whether old (e.g.
benadryl) or new (e.g.
desloratadine) antihistamines are used.
This study will look at the effect of old and new antihistamines on inhaled methacholine challenge response in individuals with mild asthma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- University of Saskatchewan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Baseline forced expiratory volume in 1s (FEV1) of 70% or more of predicted
- Methacholine provocative concentration causing a 20% fall in FEV1 16mg/ml or less
- No respiratory infection or change in allergen exposure for 4 weeks prior to screening and throughout the study
- No significant medical co-morbidities
- allergy
Exclusion Criteria:
- pregnant or breastfeeding females
- unable to withhold antihistamines, anticholinergics, long acting bronchodilators and combination therapies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: diphenhydramine
50mg dose given as two 25mg capsules
|
|
|
Active Comparator: cetirizine
10mg dose given as 1 10mg capsule and 1 placebo capsule
|
|
|
Active Comparator: desloratadine
5mg dose given as 1 5mg capsule and 1 placebo capsule
|
|
|
Placebo Comparator: placebo
given as 2 placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in methacholine pc20
Time Frame: change from baseline (pre dose) at 2 hours (post dose)
|
change from baseline (pre dose) at 2 hours (post dose)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Donald W Cockcroft, MD, University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
November 8, 2013
First Posted (Estimate)
November 15, 2013
Study Record Updates
Last Update Posted (Estimate)
April 8, 2015
Last Update Submitted That Met QC Criteria
April 7, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Sensory System Agents
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Histamine H1 Antagonists, Non-Sedating
- Diphenhydramine
- Promethazine
- Cetirizine
- Desloratadine
Other Study ID Numbers
- PHPY2013/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Meyer Children's Hospital IRCCSRecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma ChildhoodItaly
-
Tel-Aviv Sourasky Medical CenterThe Dalia and Eli Hurvitz Foundation GrantNot yet recruitingAsthma Attack | Asthma AcuteIsrael
-
University of PittsburghNational Institute of Environmental Health Sciences (NIEHS)RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma ControlUnited States
-
Vanderbilt University Medical CenterWithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Columbia UniversityChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsNot yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAPUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsRecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicSingapore
-
Johann Wolfgang Goethe University HospitalCompleted
-
Chiesi Slovenija, d.o.o.RecruitingAsthma | Asthma Bronchiale | Asthma PatientsSlovenia
-
Gümüşhane UniversıtyCompletedAsthma | Asthma Chronic | Asthma ControlTurkey (Türkiye)
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States